Newron Pharmaceuticals SpA
SIX:NWRN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.3
10.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Newron Pharmaceuticals SpA
Wall Street
Price Targets
NWRN Price Targets Summary
Newron Pharmaceuticals SpA
According to Wall Street analysts, the average 1-year price target for
NWRN
is 14.08 CHF
with a low forecast of 12.93 CHF and a high forecast of 15.75 CHF.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is NWRN's stock price target?
Price Target
14.08
CHF
According to Wall Street analysts, the average 1-year price target for
NWRN
is 14.08 CHF
with a low forecast of 12.93 CHF and a high forecast of 15.75 CHF.
What is Newron Pharmaceuticals SpA's Revenue forecast?
Projected CAGR
32%
For the last 8 years the
compound annual growth rate for
Newron Pharmaceuticals SpA's revenue is
19%.
The projected
CAGR
for the next 3 years is
32%.
You don't have any saved screeners yet
